Sun Pharma to present long-term follow-up data on UNLOXCYT™ at ASCO 2026, showing nearly 27% complete response rate.
Marksans Pharma Limited (MARKSANS) reported Q4 & FY26 financial results with historic triple: highest revenue, EBITDA & PAT ₹3,000 Cr.
Gujarat Themis Biosyn Limited (GUJTHEM) reports Q4 FY26 results with 17% revenue growth, margin expansion, and strategic acquisitions.
Yatharth Hospital & Trauma Care Services Limited (YATHARTH) reports 47% YoY growth for Q4 FY26, with strong traction across new hospitals.
Blue Jet Healthcare Limited (BLUEJET) reported a 22% QoQ increase in revenue for Q4 FY26, with PAT rising by 60%.
SMS Pharmaceuticals Limited (SMSPHARMA) reports FY26 PAT up 48% to ₹102 crore, driven by margin expansion and backward integration.
Fortis Healthcare Limited (FORTIS) announces Q4 FY26 results with consolidated revenues up 17.8% and PAT up 44.2%.
Zota Health Care Limited (ZOTA) reports strong FY26 results with revenue up 83.86% YoY, EBITDA at ₹2,597.73 lakhs, and expansion to 2,579 stores.
Torrent Pharmaceuticals Limited (TORNTPHARM) reports a 43% revenue increase in Q4 FY26, reaching ₹2,215 crore.
Lupin Limited (LUPIN) secures China approval for Oseltamivir Phosphate Oral Suspension, marking its debut in the Chinese market.